LeonaBio, Inc. (LONA)
| Market Cap | 81.07M +663.4% |
| Revenue (ttm) | n/a |
| Net Income | -129.41M |
| EPS | -16.06 |
| Shares Out | 9.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 37,523 |
| Open | 9.13 |
| Previous Close | 9.02 |
| Day's Range | 8.60 - 9.26 |
| 52-Week Range | 2.73 - 14.21 |
| Beta | 1.98 |
| Analysts | Buy |
| Price Target | 18.00 (+108.58%) |
| Earnings Date | May 7, 2026 |
About LONA
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company’s lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clini... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for LONA stock is "Buy." The 12-month stock price target is $18.0, which is an increase of 108.58% from the latest price.
News
LeonaBio to Participate in Upcoming Medical and Industry Meetings in June
BOTHELL, Wash., May 27, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unm...
LeonaBio initiated with an Overweight at Piper Sandler
Piper Sandler initiated coverage of LeonaBio (LONA) with an Overweight rating and $20 price target The company is advancing lasofoxifene, a selective estrogen receptor modulator for treatment of ER+/H...
LeonaBio Proxy statement: Proxy filing
LeonaBio filed a proxy statement on May 11, 2026, providing details for shareholder voting and corporate governance matters.
LeonaBio Proxy statement: Proxy filing
LeonaBio filed a proxy statement on May 11, 2026, providing details for shareholder voting and corporate governance matters.
LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update
Advancing Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator, a Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Exp...
LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B.
BOTHELL, Wash., May 07, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unm...
LeonaBio Quarterly report: Q1 2026
LeonaBio has published its Q1 2026 quarterly earnings report on May 7, 2026.
LeonaBio Earnings release: Q1 2026
LeonaBio released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
LeonaBio Transcript: Status update
Lasofoxifene is advancing as a promising, well-tolerated oral therapy for ER-positive, ESR1-mutated metastatic breast cancer, showing strong efficacy in combination with abemaciclib and addressing key resistance mechanisms. The pivotal ELAINE 3 trial is over halfway enrolled, with top-line data expected in 2027.
LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer
Management to be Joined by Two Clinical Leaders in the Breast Cancer Field Expected to Complete Enrollment in Ongoing ELAINE-3 Phase 3 Registrational Study of Lasofoxifene in Metastatic Breast Cancer...
LeonaBio presented data on lasofoxifene research at AACR26
LeonaBio (LONA) attended the American Association for Cancer Research Annual Meeting 2026, AACR26, where independent researchers at Virginia Commonwealth University’s Massey Comprehensive Cancer Cente...
LeonaBio price target raised to $16 from $10 at Mizuho
Mizuho raised the firm’s price target on LeonaBio (LONA) to $16 from $10 and keeps an Outperform rating on the shares post the Q4 report. The firm views LeonaBio as…
LeonaBio Registration statement: Registration filing
LeonaBio filed a registration statement on March 31, 2026, providing details about a securities offering with the SEC.
LeonaBio Registration statement: Registration filing
LeonaBio filed a registration statement on March 31, 2026, providing details about a securities offering with the SEC.
LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update
Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer P...
LeonaBio Annual report: Q4 2025
LeonaBio has published its Q4 2025 annual report on March 26, 2026.
LeonaBio Earnings release: Q4 2025
LeonaBio released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
LeonaBio Transcript: EGM 2026
Six proposals, including share issuances, an equity plan, and an increase in authorized shares, were presented and all approved by the required majority. No questions were raised by stockholders, and final results will be filed with the SEC.
LeonaBio Proxy statement: Proxy Filing
LeonaBio filed a proxy statement on March 10, 2026, providing details for shareholder voting and corporate governance matters.
LeonaBio initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of LeonaBio (LONA) with an Overweight rating and no price target The company’s lasofoxifene has been re-purposed for the treatment of ER+ metastatic breast cancer ...
LeonaBio Proxy statement: Proxy Filing
LeonaBio filed a proxy statement on February 23, 2026, providing details for shareholder voting and corporate governance matters.
LeonaBio upgraded to Outperform from Neutral at Mizuho
Mizuho upgraded LeonaBio (LONA) to Outperform from Neutral with a $10 price target which implies 120% upside potential. The firm upgraded the shares after introducing projections for LeonaBio’s new le...
LeonaBio Proxy statement: Proxy Filing
LeonaBio filed a proxy statement on February 4, 2026, providing details for shareholder voting and corporate governance matters.
LeonaBio appoints Kubik as Chief Business Officer
LeonaBio (LONA) announced the appointment of Mark Kubik as Chief Business Officer. Kubik previously served as a strategic consultant to LeonaBio.
LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer
Brings more than 25 years of biopharma business development and corporate strategy expertise Brings more than 25 years of biopharma business development and corporate strategy expertise